Superseded Protocol Documents
The documents below are protocol documents that are now superseded. These documents may not have been submitted for approval in all regions. For current protocol documents please click here.
REMAP-CAP Core Protocol
Pandemic Appendix to the Core Protocol
Pandemic Appendix - Version 1.1
Antibiotic Domain-Specific Appendix
Macrolide Duration Domain-Specific Appendix
Corticosteroid Domain-Specific Appendix
Corticosteroid DSA - Version 1
Corticosteroid DSA - Version 1.1
Corticosteroid DSA - Version 2
Corticosteroid DSA - Version 3
Corticosteroid DSA - Version 3.1
Corticosteroid DSA - Version 3.2
Corticosteroid DSA - Version 4
Corticosteroid DSA - Version 5
Corticosteroid DSA - Version 5.1
Influenza Antiviral Domain Specific Appendix
Influenza Antiviral DSA - V2.1
Influenza Antiviral DSA - V2.2
Influenza Antiviral DSA - V2.3
COVID-19 Antiviral Domain-Specific Appendix
COVID-19 Antiviral DSA - Version 1
COVID-19 Antiviral DSA - Version 2
COVID-19 Antiviral DSA - Version 2.1
COVID-19 Antiviral DSA - Version 3
COVID-19 Immune Modulation Domain-Specific Appendix
COVID-19 Immune Modulation DSA - Version 1
COVID-19 Immune Modulation DSA - Version 2
Mechanical Ventilation Domain-Specific Appendix
Mechanical Ventilation DSA - V1
Immunoglobulin Domain-Specific Appendix
Immunoglobulin DSA - Version 1
Immunoglobulin DSA - Version 1.01
Immunoglobulin DSA - Version 2.2 (Canada)
Immunoglobulin DSA - Version 2.3 (USA)
Immunoglobulin DSA - Version 2.4 (Australia)
Immunoglobulin DSA - Version 2.5 (New Zealand)
Immunoglobulin DSA - Version 3
Immunoglobulin DSA - Version 3.1
Anticoagulation Domain-Specific Appendix
Anticoagulation DSA - Version 1
Anticoagulation DSA - Version 2
Vitamin C Domain-Specific Appendix
Simvastatin Domain-Specific Appendix
Antiplatelet Domain-Specific Appendix
ACE2 RAS Domain-Specific Appendix
Endothelial Domain-Specific Appendix
Cysteamine Domain-Specific Appendix
Influenza Immune Modulation Domain-Specific Appendix
Influenza Immune Modulation DSA - V1
Influenza Immune Modulation DSA - V2
COVID-19 Antiviral (II) Domain-Specific Appendix